What is it about?
A drug working to block cannabinoid receptors in the mouse brain has shown tremendous potential as a nootropic and anti amnesic agent in mouse recognition memory Y-maze paradigm. Another drug useful mostly in vascular disorders in the brain (stroke, vascular dementia) has rather opposite effects on cognition in the same model. This is also supplemented by the chemical sub acute model of dementia.
Featured Image
Why is it important?
Two drugs acting on parallel arms in the brain both pharmacologically and anatomically have opposite effects on recognition memory retention paradigm in mouse which holds true with subacute scopolamine-induced dementia models. For the first time, these results contradict previous hypothesis and also finds the possible pro-cholinergic link for these two opposing paradoxical actions of the study drugs.
Perspectives
A pro-cholinergic mechanism linking the cannabinoid and angiotensin actions of drugs working on dementia is a novel proof, lest yet unproven / requires further exploration, to the ubiquitous actions of acetylcholine in memory functions and amnestic pathophysiology, that could be extrapolated to both neuro-degeneration and vascular dementias.
Dr RAMANUJAM NARAYANAN
PSG INSTITUTE OF MEDICAL SCIENCES & RESEARCH
Read the Original
This page is a summary of: Rimonabant improves Spatial-Novelty Object Recognition Memory and Valsartan is pro-amnesic in a dual-maze dual-scopolamine mouse model, American Psychological Association (APA),
DOI: 10.1037/e582702013-006.
You can read the full text:
Contributors
The following have contributed to this page
